Biblio

Author Title Type [ Year

]

Filters: Author is Mo, Xiao-Dong [Clear All Filters]

2024

Jiang X-Y, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation. Cell Transplant. 2024;33:9636897241257568.

Cheng C, Deng D-X, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, et al. Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basiliximab treatment. Front Oncol. 2024;14:1390438.

Li W-W, Zhang Y-M, Shen M-Z, Mo X-D. Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation. Blood Sci. 2024;6(1):e00178.

Wang Y, Liu Q-F, Wu D-P, Xu Z-L, Han T-T, Sun Y-Q, Huang F, Fan Z-P, Xu N, Chen F, et al. Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial. BMC Med. 2024;22(1):176.

Cao L-Q, Wen Q, Liu B-N, Zhao Z-Y, Zhang X-H, Xu L-P, Chen H, Wang Y, Yu L, Wang F-R, et al. Plerixafor-based mobilization and mononuclear cell counts in graft increased the risk of engraftment syndrome after autologous hematopoietic stem cell transplantation. Blood Sci. 2024;6(3):e00190.

Ma R, Zhu D-P, Zhang X-H, Xu L-P, Wang Y, Mo X-D, Lv M, Zhang Y-Y, Cheng Y-F, Yan C-H, et al. Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience. Bone Marrow Transplant. 2024.

2023

Huang Q-S, Han T-X, Chen Q, Wu J, Zhao P, Wu Y-J, He Y, Zhu X-L, Fu H-X, Wang F-R, et al. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023.

Ma L, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Effects of isolated central nervous system involvement evaluated by multiparameter flow cytometry prior to allografting on outcomes of patients with acute lymphoblastic leukemia. Front Oncol. 2023;13:1166990.

Xu Z-L, Xu L-P, Zhang Y-Y, Cheng Y-F, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, et al. Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantation. Bone Marrow Transplant. 2023.

Cao L-Q, Huo W-X, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, et al. Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients. Bone Marrow Transplant. 2023.

Wu Y-J, Liu H-X, Zhu X-L, Fu H-X, He Y, Wang F-R, Zhang Y-Y, Mo X-D, Han W, Wang J-Z, et al. Predicting short-term and long-term mortalities from sepsis in patients who receive allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2023.

Feng C-J, Zhao P, Fu H-X, Yan C-H, Wang C-C, Zhu X-L, He Y, Wang F-R, Zhang Y-Y, Mo X-D, et al. A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactivation following antiviral prophylaxis discontinuation. Am J Hematol. 2023.

Huang Q-S, Han T-X, Fu H-X, Meng H, Zhao P, Wu Y-J, He Y, Zhu X-L, Wang F-R, Zhang Y-Y, et al. Prognostic factors and outcomes in patients with septic shock after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2023.

Wu P-H, Huo W-X, Mo X-D, Wang Y, Yan C-H, Jiang H, Shen M-Z, Huang X-J, An Y-Z. Prognostic factors for patients with hematologic malignancies admitted to the intensive care unit: is allogeneic transplantation still a risk factor. Ann Hematol. 2023.

2022

Li S-Q, Xu L, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Complement of an LSC-based MRD assay to the traditional MFC method for relapse prediction of AML: a prospective study. Blood. 2022.

Deng R-X, Zhu X-L, Zhang A-B, He Y, Fu H-X, Wang F-R, Mo X-D, Wang Y, Zhao X-Y, Zhang Y-Y, et al. Machine learning algorithm as a prognostic tool for venous thromboembolism in allogeneic transplant patients. Transplant Cell Ther. 2022.

Luo X-Y, Kong Y, Lv M, Mo X-D, Wang Y, Xu L-P, Zhang X-H, Huang X-J, Tang F-F. The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2022.

2021

Xu L-P, Yu Y, Cheng Y-F, Zhang Y-Y, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, et al. Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. Br J Haematol. 2021.

Cao L-Q, Zhou J-R, Zhang X-H, Xu L-P, Wang Y, Chen Y-H, Chen H, Chen Y, Han W, Yan C-H, et al. A scoring system for predicting the prognosis of late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021.

Wang J-Z, Huang X-J, Zhang Y-Y, Tang F-F, Han T-T, Mo X-D, Sun Y-Q, Chen Y-H, Wang Y, Zhang X-H, et al. Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia. Chin Med J (Engl). 2021;134(20):2518-2520.

Niu L-T, Wang Y-Q, Wong CCL, Gao S-X, Mo X-D, Huang X-J. Targeting IFN-γ-inducible lysosomal thiol reductase overcomes chemoresistance in AML through regulating the ROS-mediated mitochondrial damage. Transl Oncol. 2021;14(9):101159.

2020

Zeng Q-Z, Zhang Y-Y, Wu Y-J, Zhang Z-Y, Zhang J-N, Fu H-X, Wang J-Z, Wang F-R, Yan C-H, Mo X-D, et al. Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.

Liu J, Gao H, Xu L-P, Mo X-D, Liu R, Liang S, Wu N, Wang M, Wang Z, Chang Y-J, et al. Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2 T cells activities after hematopoietic transplantation for blood malignancies. J Immunother Cancer. 2020;8(1).

Xu Z-L, Cheng Y-F, Zhang Y-Y, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, Tang F-F, et al. The incidence, clinical outcome and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transplant. 2020:e14160.

Tang F-F, Sun Y-Q, Mo X-D, Lv M, Chen Y-H, Wang Y, Xu L-P, Zhang X-H, Huang X-J. The incidence, risk factors, and outcomes of primary prolonged isolated thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.

Pages